TRAC and leukemia: It has been shown that deletion of T Cell Receptor Alpha Constant (TRAC), B2M, and PDCD1 in universal EGFRvIII and CD19-CAR-T cells enhanced their anti-tumor responses, respectively, against both solid and hematologic malignancies (glioblastoma and leukemia).